Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.
ICI-induced inflammatory myositis (IIM) is a recognized irAE with significant morbidity and potential for life-threatening overlap syndromes. Whether polymyositis (PM) and dermatomyositis (DM) carry differential pharmacovigilance signals across ICI drug classes has not been syst…